INTRODUCTION AND OBJECTIVES: Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) occurs at a high rate. We previously reported that most IVR occurs around the site of damage to the bladder mucosa within one year of RNU and that IVR after RNU affects the oncological outcomes of patients with non-muscle invasive UTUC. Seeding of UTUC cells on the damaged bladder wall during RNU is considered to be a cause of IVR. Thus, efficacy of early ureteral ligation (EUL) on prevention of IVR after RNU for UTUC was prospectively evaluated in a multicenter clinical trial.
INTRODUCTION AND OBJECTIVES: Intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC) occurs at a high rate. We previously reported that most IVR occurs around the site of damage to the bladder mucosa within one year of RNU and that IVR after RNU affects the oncological outcomes of patients with non-muscle invasive UTUC. Seeding of UTUC cells on the damaged bladder wall during RNU is considered to be a cause of IVR. Thus, efficacy of early ureteral ligation (EUL) on prevention of IVR after RNU for UTUC was prospectively evaluated in a multicenter clinical trial.
METHODS: Patients who underwent RNU for UTUC between 2012 and 2013 at 15 institutions participating in the Tohoku Urological Evidence-Based Medicine Study Group were enrolled. Those with bladder cancer before RNU or metastasis at the time of UTUC diagnosis were excluded. We defined EUL as ligating the ureter as soon as possible after expanding the retroperitoneal space and before ligating the renal artery. A historical control was extracted from 454 patients from the same group who underwent RNU for UTUC between 2000 and 2011, using propensity score-matched analysis. The IVR-free survival rates following RNU were prospectively analyzed using Kaplan-Meier curves and the log-rank test. Factors predicting IVR were assessed using multivariate analyses. The Ethics Committee at Tohoku University Hospital approved the study protocol.
RESULTS: Seventy-four of the 148 patients had EUL and 74 patients in the control group did not undergo ureteral ligation. With a median follow-up of 21 months, 17 (23%) patients in the EUL group had IVR. The 1-and 2-year IVR-free survival rates in the EUL and control groups were 81% and 76%, respectively and 75% and 63%, respectively (p¼0.201). The 1-and 2-year IVR-free survival rates among patients with renal pelvic cancer in the EUL and control groups were 89% and 86%, respectively and 74% and 64%, respectively (p¼0.032). However, IVR-free survival rates were similar among the patients with ureteral cancer. Multivariate analyses of a subset of patients with renal pelvic cancer selected EUL as an independent predictor of IVR after RNU (hazard ratio, 0.37; p¼0.049).
CONCLUSIONS: Early ureteral ligation decreased the rate of IVR after RNU among patients with renal pelvic cancer. This might result from the prevention of floating UTUC cells during RNU. Thus, EUL might contribute to the prevention of IVR after RNU for renal pelvic cancer.
Source of Funding: none

MP78-05
INTRAVESICAL IRRIGATION PREVENTS BLADDER CARCINOMA RECURRENCE AFTER NEPHROURETERECTOMY Satoshi Yamamoto*, Shinichi Sakamoto, Tomokazu Sazuka, Chiba, Japan; Toshihito Inoue, Kazuyoshi Nozumi, Kazuto Chiba, Kanetaka Miyazaki, Atsushi Inoue, Maki Nagata, Yokohama, Japan; Tomohiko Ichikawa, Chiba, Japan INTRODUCTION AND OBJECTIVES: The effectiveness of intravesical irrigation with physiological saline solution or distilled water for prevention of bladder carcinoma recurrence in upper urinary tract urothelial carcinoma (UUT-UC) was examined.
METHODS: The study involved UUT-UC patients without distant metastasis who underwent laparoscopic nephroureterectomy from 2001 to 2014. Those who had a history of bladder carcinoma, had undergone neoadjuvant therapy and had bladder carcinoma confirmed before surgery were excluded. Cases that did and did not involve intravesical irrigation were compared for bladder carcinoma recurrence rates within 2 years after surgery. Physiological saline solution or distilled water was used for irrigation, which was performed only during surgery.
RESULTS: Irrigation was performed in 48 (distilled water, 26 cases; physiological saline solution, 22 cases) of the 74 cases in our study. Bladder carcinoma recurrence was observed in 25 patients within 2 years. Comparison between the irrigation and non-irrigation groups revealed that recurrence rates were significantly lower in the irrigation group (irrigation group vs non-irrigation group: 25.0% vs 50.0%, HR0.29, P¼0.013). No significant difference in recurrence rate were observed based on the type of irrigation (P¼0.96). No adverse event was confirmed in the irrigation group. On multivariate analysis, irrigation was the independent predictive factor involved in the prevention of recurrence (HR0.32, P¼ 0.0075).
CONCLUSIONS: Intravesical irrigation during laparoscopic nephroureterctomy may be a useful option in preventing postoperative bladder carcinoma recurrence in UUT-UC. METHODS: A phase II trial of PPV immunotherapy was conducted for patients with mUTUC refractory to the standard chemotherapy. Eligible patients were human leukocyte antigen (HLA) A02, A24, A26, or A03 superfamily positive. A maximum of four HLAmatched peptides was selected based on the preexisting immunoglobulin G (IgG) responses against the 31 warehouse peptides and administered every 1 to 2 week. The overall survival (OS) time was estimated by the Kaplan-Meier method. Association between prevaccination biomarkers, including immune responses, and OS were evaluated by univariate and multivariate analyses with the Cox regression model, and by the Kaplan-Meier method with the logrank test.
Source of
RESULTS: Among 48 patients entered, 28 patients received PPV combined with salvage chemotherapy based on physicians 0 choice, and 20 patients received PPV alone since of ineligible due to potential intolerance to chemotherapy. Although no PPV-related severe adverse events were noted, 1 or 12 of 28 patients of the former group dropped before 1st or 2nd cycle due to disease progression, whereas dropped 7 or 16 of 20 patients of the latter group (p¼0.002). Peptidespecific cytotoxic T lymphocyte (CTL) activity before PPV was scarcely detectable, but boosted in about half of patients tested after PPV. Median survival time (MST) of all 48 patients was 7.3 months (M) with 13.0 M for 28 patients under PPV and salvage chemotherapy and 4.5 M for 20 patients under PPV alone (p¼0.08). Unfavorable prognostic factors by multivariate Cox regression analysis were higher numbers of Bellmunt risk factors (p¼0.027) and higher levels of pre-vaccination BAFF (p¼0.002). Notably, both peptide-specific CTL and IgG boosting were favorable prognostic factors, suggesting a causal relationship between immune responses and clinical efficacy in PPV.
CONCLUSIONS: Further clinical trials of PPV would be warranted for mUTUC because of the safety, immune boosting, and potential clinical benefits. Our data might provide promising evidence of clinical benefit of PPV for patients with mUTUC refractory to the standard chemotherapy.
Source of Funding: none
MP78-07 GENDER-SPECIFIC DIFFERENCES IN CANCER-SPECIFIC SURVIVAL AFTER NEPHROURETERECTOMY WITH BLADDER CUFF FOR PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA
Teruo Inamoto*, Kiyoshi Takahara, Naokazu Ibuki, Takatsuki, Japan; Hideyasu Matsuyama, Ube, Japan; Kiyohide Fujimoto, Kashihara, Japan; Hiroaki Shiina, Shimane, Japan; Shigeru Sakano, Kazuhiro Nagao, Ube, Japan; Yoshihiro Tatsumi, Kashihara, Japan; Haruhito Azuma, Takatsuki, Japan; Nishinihon Uro-Oncology Collaborative Group, Ube, Japan INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinoma (UTUC) show heterogeneous outcome after nephroureterectomy (NU). Despite gender-specific differences, no comparative studies exist for this tumor. The aim of this investigation was to describe tumor characteristics, and survival in patients with UTUC in a multicenter-based cohort, with special reference to gender-related differences.
METHODS: Cancer-specific survival (CSS) of 1304 UTUC patients without neoadjuvant chemotherapy staged any pT, pN0-1, M0 after NU were analyzed in a retrospective multicenter study. Median follow-up period was 34 months. The influence of different clinical and histopathologic variables on CSS was determined through uni-and multi-variate Cox regression analyses.
RESULTS: In total, 916 (70.2%) patients were male and 388 (29.8%) were female. Compared to men, women were more likely to have advanced tumor stages (p ¼ 0.007), higher grade (p < 0.001) and lympho-vascular invasion (LVI) (p < 0.001). There was statistical difference in disease recurrence and cancer-specific survival between both genders when analyzed as a group. In LVI status-adjusted analyses, women without LVI were more likely to die of UTUC compared to the male counterparts (p ¼ 0.011). Logistic regression modeling, female gender (HR ¼ 1.42, p ¼ 0.037), LVI (HR ¼ 1.61, p ¼ 0.004), and ECOG performance status (HR ¼ 1.47, p ¼ 0.007) significantly worsened cancer specific deaths. In gender-specific multivariable analyses that adjusted for standard clinico-pathologic features, positive urine cytology at diagnosis (p ¼ 0.001), tumor grade (p ¼ 0.007), LVI (p ¼ 0.005), and pathologic tumor stage (p < 0.001) were independent predictors for CSS.
CONCLUSIONS: In this multicenter-based cohort, female gender was associated with inferior cancer-specific and relative survival. Women present with more aggressive tumor biologic features at NU, this translated into inferior outcomes compared to men in LVIspecific analyses in our cohort. Positive urine cytology at diagnosis, tumor grade, LVI, and pathologic tumor stage, were the factors influencing the course of disease in both genders. METHODS: We identified patients who presented with mUTUC at diagnosis in the National Cancer Data Base (NCDB) from 2004 to 2014. Only patients who had multi-agent systemic chemotherapy with or without CS were included. Multivariable logistic regression was performed to identify the predictors of receiving CS. Kaplan-Meier survival, log-rank test, and multivariable Cox regression controlled for demographics, socioeconomic factors, and tumor characteristics were used to compare the overall survival (OS) between CS and no CS groups.
RESULTS: We included 657 patients in our study of which 202 (30.75%) underwent CS. Logistic regression showed that patients who were older (OR ¼ 0.98, 95% CI ¼ 0.96-1.00, P ¼0.038), diagnosed with ureteral cancer (OR ¼ 0.42, 95% CI ¼ 0.27-0.66, P < 0.001), and had cN+ disease (OR ¼ 0.33, 95% CI ¼ 0.21-0.54, P < 0.001) were less likely to receive CS. Patients who were treated at a community hospital (OR ¼ 1.96, 95% CI ¼ 1.35-2.86, P < 0.001) were more likely to receive CS. No difference was found in Charlson comorbidity index between the CS and no CS groups (P ¼ 0.434). CS group had significantly higher median OS than no CS group (13.4 vs. 10.3 months, log-rank test P < 0.001, Figure 1 ). Cox regression showed that compared with chemotherapy alone, chemotherapy combined with CS was significantly associated with improved OS (HR ¼ 0.57, 95%CI ¼ 0.44-0.74, P < 0.001).
CONCLUSIONS: Consistent with various other malignancies, CS appears to provide a survival benefit for mUTUC. However, our study is limited by the observational study design. Studies with higher level of evidence, especially randomized controlled trials are needed to validate the findings and to better identify the patients who are most likely to benefit from CS.
